ʻO ka luaʻana o ka maʻi kanulau maʻi i hōʻeaʻia i ka pūnaewele hōʻailona Cancer Drugs

ʻO kekahi mau maʻi i loaʻa ka maʻi kanulau āpau ma United Kingdom, ma hope o ka hoʻoholo mua o ka National Institute for Health and Care Excellence (NICE).

ʻO ka hui o nā lāʻau lapaʻau hōʻoia (Kisqali) a Hoʻopiʻi (Faslodex), i hōʻikeʻia i ka hoʻomauʻana i ka maʻi ma kahi ho'āʻo hoʻokolohua,ʻo ia NICE ma ka lāʻoʻApelila 2019 no ka mea,ʻaʻole i hāʻawi ka lāʻau i ka waiwai i ke kālā.

Akāʻo nā'ōlelo kū'ē'ē ua hiki i ka NICE ke'ōlelo i nā maʻi NHS maʻEnelani e komo i ka lāʻau lapaʻau. It hui pū me kekahi hui like e like me ka Fund Cancer Drugs, ke uku nei no ka hiki mua i nā hōʻailonaʻokoʻa.

Ma kēiaʻano, e nānā houʻo NICE i ka huiʻana e pono ke hoʻolakoʻia i nā maʻi hou i ka manawa e hoʻopauʻia ai ka ho'āʻo hoʻokolohua ma ka pauʻana o 2020.

Rose Hinahina, Cancer Research UK ka pilikino E pili manakia i ka "olelo maikai." Aloha mai la ia mea, ua nui e ike Nice, NHS England a me ribociclib Hookah ka hana pu, e hoʻopaʻa i ka iapaau ana hiki E Ma hope o ka paipai loiloi mua rejection.

ʻO nā lāʻau'aloʻolo i'ōleloʻia no ka Waihona Lapaʻau Cancer iʻEnelani aia i ka uku kālāʻia e ka NHS ma Northern Ireland a me Wales, i mea e loaʻa ai nā maʻi i nā poʻe maʻi ma laila. ʻO nā koho e pili ana i nā lāʻau a ka NHS e uku ai ma Scotland e hanaʻia e ka Scottish Medicine Consortium.

Ke kali nei ka chemotherapy

ʻO ka lapaʻau i hoʻohuiʻia iʻikeʻia he ribociclib,ʻo ia hoʻi kahi lāʻau inu lāʻau i hoʻohuiʻia, me ka loli,ʻo ia ka hormone therapy.

Hiki ke hui pūʻia me ka poʻe maʻi me ka maʻi āpau o ka umauma e hohola ma ka umauma a ma nā wahi'ē aʻe o ke kino. Akā no nā mea wale nō i hanaʻia ka maʻi kanesa e ka estrogen hormones a me ka hōʻoiaʻanaʻole no kahi mole i kapaʻiaʻo HER2, a ua hanaʻia me ka hormone therapy ma mua.

Nīnauʻo NICE he mea pono ka hui pūʻana no ka hoʻomaʻamaʻaʻana i nā maʻi me ka maʻi hōʻehaʻeha.

"He mea nui nā hōʻailona hiki ke hoʻoneʻe i ka uluʻana o ka maʻi no ka mea he mau manawa kīnāʻole ia no ka chemotherapy, a ke hoʻokaʻulua nei i ka pono no ka hoʻohanaʻana i nā mea'ē aʻe." - Meindert Boysen, luna o ka NICE Center no ka Health Technology Evaluation

"ʻO nā hōʻike hoʻokolohua hōʻailona e hōʻike ana e hiki i kēia koho koho ke hāʻawi i nā maʻi iʻoi aʻe ka koʻikoʻi," wahi a Gray, e pili ana i kahi ke aʻoʻia e hoʻohālikelike ana i ka huiʻana i kahi lāʻau hōʻailona (placebo) ma nā 726 wāhine i hele i loko o ka moeʻuhane.

ʻO nā poʻe maʻi e mālama ana i nā lāʻau maʻamau no nā poʻe 20.5 ma kaʻawelike, i ka hoʻohālikelikeʻana me 12.8 i ka mea maʻamau i ka poʻe lawe pono a placebo.

Akā,ʻoi aku i ka hapalua o ka poʻe i loaʻa i ka makeʻana o ke koko (Neutropenia).

Nā koho'ē aʻe no nā maʻi

ʻO ka hui pūʻana o ka ribociclib a me ka fullower ua ulu i ka papa ulu e'āponoʻia ana no nā kānaka me kēiaʻano o ka maʻi lapaʻau. E hāʻawi ana i kahi koho hou no nā maʻi i hōʻalo i ka hanuʻana i ka paneʻana i ka maʻi hormone.

Nice Olelo aku la o ka combo E haʻihaʻi wale e hoʻohana i ka hihia Where ka wale 'ē aʻe koho mea he huihui' ana o ka okoa ai 'elua, ua kapaia hōmona Inc ke aho exemestane (Aromasin) a me ka hoʻomāka lāʻau everolimus (Afinitor).

"Ke hāʻawi aku nei ka hōʻailona i kahiʻokoʻa'ē aʻe iʻaeʻia e nā lāʻau lapaʻau e like me ka lāʻau lapaʻau - he mea nui ia no nā hōʻailona o kekahi mau maʻi," wahi a Gray. "A no ka mea ua hāʻawiʻia ia mea no ka Fund Cancer Drugs, e hiki i nā maʻi ke komo i ka lāʻau lapaʻau."

ʻO nā maʻi e lawe ana i ka momona a me ka loiloi e pono i nā huli a me nā ho'āʻo o ka naʻau e hoʻomaopopo pono i ka hanaʻana o ke ake. ʻO ka hui pūʻana o ka hōʻailona (Verzenio) a me ka loiloi.

Uaʻike muaʻia kēiaʻatikala https://www.cancerresearchuk.org/about-us/cancer-news/news-report/2019-07-17-second-breast-cancer-treatment-combo-added-to-englands-cancer-drugs-fund